CIViC Evidence Items

14 evidence items indexed

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
D	ESR1	L536Q	Predictive	Supports	Sensitivity/Response	Breast Cancer	Tamoxifen,Fulvestrant	Robinson et al., 2013
D	ESR1	D538G	Predictive	Supports	Sensitivity/Response	Breast Cancer	Fulvestrant,Tamoxifen	Robinson et al., 2013
D	ESR1	Y537C	Predictive	Supports	Sensitivity/Response	Breast Cancer	Fulvestrant,Tamoxifen	Robinson et al., 2013
D	ESR1	Y537N	Predictive	Supports	Sensitivity/Response	Breast Cancer	Tamoxifen,Fulvestrant	Robinson et al., 2013
D	ESR1	Y537S	Predictive	Supports	Sensitivity/Response	Breast Cancer	Fulvestrant,Tamoxifen	Robinson et al., 2013
B	ESR1	Overexpression	Predictive	Supports	Sensitivity/Response	Breast Cancer	Palbociclib,Letrozole	Finn et al., 2015
A	ESR1	Mutation	Predictive	Supports	Sensitivity/Response	Breast Cancer	Elacestrant	Bidard et al., 2022
D	ESR1	L536Q	Predictive	Supports	Resistance	Breast Cancer	Hormone Therapy	Toy et al., 2013
D	ESR1	D538G	Predictive	Supports	Resistance	Breast Cancer	Hormone Therapy	Toy et al., 2013
D	ESR1	Y537C	Predictive	Supports	Resistance	Breast Cancer	Hormone Therapy	Toy et al., 2013
D	ESR1	Y537N	Predictive	Supports	Resistance	Breast Cancer	Hormone Therapy	Toy et al., 2013
D	ESR1	Y537S	Predictive	Supports	Resistance	Breast Cancer	Hormone Therapy	Toy et al., 2013
D	ESR1	S463P	Predictive	Supports	Resistance	Estrogen-receptor Positive Breast Cancer	Aromatase Inhibitor	Toy et al., 2013
B	ESR1	D538G	Predictive	Does Not Support	Sensitivity/Response	Breast Cancer	Palbociclib,Letrozole	PMID 27556863